Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor in development for use with other antiretroviral therapies to treat human immunodeficiency virus type 1 (HIV-1) infection. Doravirine metabolism predominantly occurs via cytochrome P450 3A with <10% of elimination occurring via t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Ankrom, Wendy, Yee, Ka Lai, Sanchez, Rosa I., Adedoyin, Adedayo, Fan, Li, Marbury, Thomas, Preston, Richard A., Iwamoto, Marian, Khalilieh, Sauzanne G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2018
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105803/
https://ncbi.nlm.nih.gov/pubmed/29891610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00326-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados